Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech — if it can beat out stiff competition from the likes of Pfizer Inc.
Alnylam’s Amvuttra was approved to treat transthyretin amyloid cardiomyopathy, or ATTR-CM, the company said Thursday in a statement. The shares rose as much as 12% in Friday trading in New York, the most intraday since August 2024. They had gained more than two-thirds over the past year through Thursday’s close as investors anticipated the clearance.
Amvuttra will now be available to treat ATTR-CM, ...
